The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus

Joseph Muenzer, Olaf Bodamer, Barbara Burton, Lorne Clarke, Gudrun Schulze Frenking, Roberto Giugliani, Simon Jones, Maria Verónica Muñoz Rojas, Maurizio Scarpa, Michael Beck, Paul Harmatz

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Intravenous enzyme replacement therapy (ERT) with idursulfase for Hunter syndrome has not been demonstrated to and is not predicted to cross the blood-brain barrier. Nearly all published experience with ERT with idursulfase has therefore been in patients without cognitive impairment (attenuated phenotype). Little formal guidance is available on the issues surrounding ERT in cognitively impaired patients with the severe phenotype. An expert panel was therefore convened to provide guidance on these issues. The clinical experience of the panel with 66 patients suggests that somatic improvements (e.g., reduction in liver volume, increased mobility, and reduction in frequency of respiratory infections) may occur in most severe patients. Cognitive benefits have not been seen. It was agreed that, in general, severe patients are candidates for at least a 6-12-month trial of ERT, excluding patients who are severely neurologically impaired, those in a vegetative state, or those who have a condition that may lead to near-term death. It is imperative that the treating physician discuss the goals of treatment, methods of assessment of response, and criteria for discontinuation of treatment with the family before ERT is initiated. Conclusion: The decision to initiate ERT in severe Hunter syndrome should be made by the physician and parents and must be based on realistic expectations of benefits and risks, with the understanding that ERT may be withdrawn in the absence of demonstrable benefits.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalEuropean Journal of Pediatrics
Volume171
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Mucopolysaccharidosis II
Enzyme Replacement Therapy
Consensus
Physicians
Persistent Vegetative State
Phenotype
Blood-Brain Barrier
Respiratory Tract Infections
Parents
Liver
Therapeutics

Keywords

  • Cognitive impairment
  • Enzyme replacement therapy
  • Hunter syndrome
  • Idursulfase
  • Mucopolysaccharidosis II
  • Severe phenotype

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Muenzer, J., Bodamer, O., Burton, B., Clarke, L., Frenking, G. S., Giugliani, R., ... Harmatz, P. (2012). The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. European Journal of Pediatrics, 171(1), 181-188. https://doi.org/10.1007/s00431-011-1606-3

The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. / Muenzer, Joseph; Bodamer, Olaf; Burton, Barbara; Clarke, Lorne; Frenking, Gudrun Schulze; Giugliani, Roberto; Jones, Simon; Rojas, Maria Verónica Muñoz; Scarpa, Maurizio; Beck, Michael; Harmatz, Paul.

In: European Journal of Pediatrics, Vol. 171, No. 1, 01.01.2012, p. 181-188.

Research output: Contribution to journalArticle

Muenzer, J, Bodamer, O, Burton, B, Clarke, L, Frenking, GS, Giugliani, R, Jones, S, Rojas, MVM, Scarpa, M, Beck, M & Harmatz, P 2012, 'The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus', European Journal of Pediatrics, vol. 171, no. 1, pp. 181-188. https://doi.org/10.1007/s00431-011-1606-3
Muenzer, Joseph ; Bodamer, Olaf ; Burton, Barbara ; Clarke, Lorne ; Frenking, Gudrun Schulze ; Giugliani, Roberto ; Jones, Simon ; Rojas, Maria Verónica Muñoz ; Scarpa, Maurizio ; Beck, Michael ; Harmatz, Paul. / The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. In: European Journal of Pediatrics. 2012 ; Vol. 171, No. 1. pp. 181-188.
@article{b34c3ebddb8a49608b2549897a09abb4,
title = "The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus",
abstract = "Intravenous enzyme replacement therapy (ERT) with idursulfase for Hunter syndrome has not been demonstrated to and is not predicted to cross the blood-brain barrier. Nearly all published experience with ERT with idursulfase has therefore been in patients without cognitive impairment (attenuated phenotype). Little formal guidance is available on the issues surrounding ERT in cognitively impaired patients with the severe phenotype. An expert panel was therefore convened to provide guidance on these issues. The clinical experience of the panel with 66 patients suggests that somatic improvements (e.g., reduction in liver volume, increased mobility, and reduction in frequency of respiratory infections) may occur in most severe patients. Cognitive benefits have not been seen. It was agreed that, in general, severe patients are candidates for at least a 6-12-month trial of ERT, excluding patients who are severely neurologically impaired, those in a vegetative state, or those who have a condition that may lead to near-term death. It is imperative that the treating physician discuss the goals of treatment, methods of assessment of response, and criteria for discontinuation of treatment with the family before ERT is initiated. Conclusion: The decision to initiate ERT in severe Hunter syndrome should be made by the physician and parents and must be based on realistic expectations of benefits and risks, with the understanding that ERT may be withdrawn in the absence of demonstrable benefits.",
keywords = "Cognitive impairment, Enzyme replacement therapy, Hunter syndrome, Idursulfase, Mucopolysaccharidosis II, Severe phenotype",
author = "Joseph Muenzer and Olaf Bodamer and Barbara Burton and Lorne Clarke and Frenking, {Gudrun Schulze} and Roberto Giugliani and Simon Jones and Rojas, {Maria Ver{\'o}nica Mu{\~n}oz} and Maurizio Scarpa and Michael Beck and Paul Harmatz",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/s00431-011-1606-3",
language = "English",
volume = "171",
pages = "181--188",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus

AU - Muenzer, Joseph

AU - Bodamer, Olaf

AU - Burton, Barbara

AU - Clarke, Lorne

AU - Frenking, Gudrun Schulze

AU - Giugliani, Roberto

AU - Jones, Simon

AU - Rojas, Maria Verónica Muñoz

AU - Scarpa, Maurizio

AU - Beck, Michael

AU - Harmatz, Paul

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Intravenous enzyme replacement therapy (ERT) with idursulfase for Hunter syndrome has not been demonstrated to and is not predicted to cross the blood-brain barrier. Nearly all published experience with ERT with idursulfase has therefore been in patients without cognitive impairment (attenuated phenotype). Little formal guidance is available on the issues surrounding ERT in cognitively impaired patients with the severe phenotype. An expert panel was therefore convened to provide guidance on these issues. The clinical experience of the panel with 66 patients suggests that somatic improvements (e.g., reduction in liver volume, increased mobility, and reduction in frequency of respiratory infections) may occur in most severe patients. Cognitive benefits have not been seen. It was agreed that, in general, severe patients are candidates for at least a 6-12-month trial of ERT, excluding patients who are severely neurologically impaired, those in a vegetative state, or those who have a condition that may lead to near-term death. It is imperative that the treating physician discuss the goals of treatment, methods of assessment of response, and criteria for discontinuation of treatment with the family before ERT is initiated. Conclusion: The decision to initiate ERT in severe Hunter syndrome should be made by the physician and parents and must be based on realistic expectations of benefits and risks, with the understanding that ERT may be withdrawn in the absence of demonstrable benefits.

AB - Intravenous enzyme replacement therapy (ERT) with idursulfase for Hunter syndrome has not been demonstrated to and is not predicted to cross the blood-brain barrier. Nearly all published experience with ERT with idursulfase has therefore been in patients without cognitive impairment (attenuated phenotype). Little formal guidance is available on the issues surrounding ERT in cognitively impaired patients with the severe phenotype. An expert panel was therefore convened to provide guidance on these issues. The clinical experience of the panel with 66 patients suggests that somatic improvements (e.g., reduction in liver volume, increased mobility, and reduction in frequency of respiratory infections) may occur in most severe patients. Cognitive benefits have not been seen. It was agreed that, in general, severe patients are candidates for at least a 6-12-month trial of ERT, excluding patients who are severely neurologically impaired, those in a vegetative state, or those who have a condition that may lead to near-term death. It is imperative that the treating physician discuss the goals of treatment, methods of assessment of response, and criteria for discontinuation of treatment with the family before ERT is initiated. Conclusion: The decision to initiate ERT in severe Hunter syndrome should be made by the physician and parents and must be based on realistic expectations of benefits and risks, with the understanding that ERT may be withdrawn in the absence of demonstrable benefits.

KW - Cognitive impairment

KW - Enzyme replacement therapy

KW - Hunter syndrome

KW - Idursulfase

KW - Mucopolysaccharidosis II

KW - Severe phenotype

UR - http://www.scopus.com/inward/record.url?scp=84857061064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857061064&partnerID=8YFLogxK

U2 - 10.1007/s00431-011-1606-3

DO - 10.1007/s00431-011-1606-3

M3 - Article

C2 - 22037758

AN - SCOPUS:84857061064

VL - 171

SP - 181

EP - 188

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 1

ER -